Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.30 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412054 | 1.00 | RARB (0.35) | RARBTAAR1RARARARGMAOB | |
| SCHEMBL13412056 | 0.91 | CHKA (0.33) | RARBCHKA | |
| SCHEMBL13412053 | 0.89 | MAOB (0.34) | RARBTAAR1RARARARGMAOB | |
| SCHEMBL18458484 | 0.87 | GPR52 (0.40) | RARBTAAR1RARARARGHCAR2 | |
| SCHEMBL20849604 | 0.87 | GPR52 (0.40) | RARBTAAR1RARARARGHCAR2 | |
| SCHEMBL15180192 | 0.87 | RARB (0.40) | RARBTAAR1RARARARGMAOB | |
| SCHEMBL13577669 | 0.87 | RARB (0.40) | RARBTAAR1RARARARGMAOB | |
| SCHEMBL11957385 | 0.87 | FFAR4 (0.39) | RARBTAAR1RARARARGKIF11 | |
| SCHEMBL16258133 | 0.87 | FFAR4 (0.39) | RARBTAAR1RARARARGKIF11 | |
| SCHEMBL17402085 | 0.87 | RARB (0.42) | RARBTAAR1RARARARGMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2837670-B1 | FLUOROBIPHENYL-CONTAINING COMPOSITION | DAINIPPON INK & CHEMICALS (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-9441160-B2 | Fluorobiphenyl-containing composition | DIC CORPORATION (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9441160-B2 | Fluorobiphenyl-containing composition | DIC CORPORATION (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9181478-B2 | Fluorobiphenyl-containing composition | DIC CORPORATION (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9181478-B2 | Fluorobiphenyl-containing composition | DIC CORPORATION (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150291881-A1 | FLUOROBIPHENYL-CONTAINING COMPOSITION | DIC CORPORATION (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150291881-A1 | FLUOROBIPHENYL-CONTAINING COMPOSITION | DIC CORPORATION (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150252263-A1 | FLUOROBIPHENYL-CONTAINING COMPOSITION | DIC CORPORATION (JP) | 2015-09-10 | — | — | US | disclosed |
| US-20150252263-A1 | FLUOROBIPHENYL-CONTAINING COMPOSITION | DIC CORPORATION (JP) | 2015-09-10 | — | — | US | disclosed |
| US-20150053891-A1 | FLUOROBIPHENYL-CONTAINING COMPOSITION | DIC CORPORATION (JP) | 2015-02-26 | — | — | US | disclosed |
| US-7732021-B2 | Liquid crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732021-B2 | Liquid crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7635505-B2 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2009-12-22 | — | — | US | disclosed |
| US-7635505-B2 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2009-12-22 | — | — | US | disclosed |
| US-20090194738-A1 | Liquid-crystalline medium | MANABE ATSUTAKA | 2009-08-06 | — | — | US | disclosed |
| US-20090194738-A1 | Liquid-crystalline medium | MANABE ATSUTAKA | 2009-08-06 | — | — | US | disclosed |
| US-20080277623-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080277623-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080128653-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-06-05 | — | — | US | disclosed |
| US-20080128653-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080277623-A1 | Liquid Crystalline Medium | CHRM1, NEFM, CCNT1 | RARB 2516/4885TAAR1 752/4885RARA 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.